A Phase 3 interventional study of tenecteplase in Heart Arrest, sponsored by Boehringer Ingelheim. Terminated at 68 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-29.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Heart Arrest with a site in Germany — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Germany.
Among the 38 studies in Heart Arrest with a site in Germany, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2004, is the only one in phase 3, and was the 1st registered.
926 studies on the registry are indexed under Heart Arrest; 226 are open to participants now.
Browse Heart Arrest studies →8 of the 38 studies in Heart Arrest with a site in Germany are open now. Recruiting first, the newest first:
neurescue · Sites in Germany
Ages 18–80
Muehlenkreiskliniken, MKK · Sites in Germany
Ages 18+
University Hospital, Ghent · Sites in Germany, Austria, Belgium and 5 more countries
Ages 18+
Lund University · Sites in Germany, Finland, Sweden
Ages 18–100
Leipzig Heart Science gGmbH · Sites in Germany
Ages up to 18
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,050 is above the median of 100 across 518 interventional studies indexed under Heart Arrest.
Median enrollment 150 across the 23 interventional studies, 200 across the 15 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 38 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 1 study filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Arrest with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT07026773University Hospital, GhentValidity of ICU Clinician's Appraisal of Proportionality in CPR | 2026-12-30 |
| NCT06793033neurescueA Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support | 2027-01 |
| NCT07607808University Hospital, AachenPsychological Stress and Support Needs of Volunteer First Responders After Smartphone-based Cardiac Arrest Alerts | 2027-05-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies in Heart Arrest with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The general aim of this study is to compare the efficacy and safety of tenecteplase to standard treatment during cardiopulmonary resuscitation in patients suffering from out-of-hospital cardiac arrest.
The trial is a prospective, international, multi-centre, randomised (1:1), double-blind, parallel group comparison conducted for investigating the efficacy and safety of tenecteplase and placebo in patients with cardiac arrest of presumed cardiac origin.
Approximately 1300 patients (two groups of 650 patients; tenecteplase or matching placebo) suffering from witnessed (by eye or ear) out-of-hospital cardiac arrest of presumed cardiac origin, who are treated with ALS-CPR will be randomised at approximately 40 study centres. Randomisation is done immediately after insertion of an IV line is established. Study drug application, as a single IV bolus over 5-10 seconds, should be done immediately after the first vasopressor application during the ALS-CPR procedure.
PCI facilities will be required at all participating sites, i.e. hospitals receiving patients.
Study Hypothesis:
The primary aim of the trial is to demonstrate superiority in the intent-to-treat analysis of tenecteplase over placebo with regard to primary endpoint as the incidence of 30-day survival (30daysurv).
Comparison(s):
Group A (experimental; fibrinolytic treatment) Tenecteplase, as a single IV bolus over 5-10 seconds, immediately after first vasopressor dosage during standardised ALS-CPR procedures according to the International CPR Guidelines.
Group B (reference) Placebo, as a single IV bolus over 5-10 seconds, immediately after first vasopressor dosage during standardised ALS-CPR procedures according to the International CPR Guidelines.
Patients, indicated for pre-hospital ALS-CPR procedures* must fulfil the following inclusion criteria:
Subjects who meet any of the following criteria will be excluded from randomisation into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The primary endpoint of this study is the 30-day survival rate
Time frame: 30 days
The co-primary endpoint of this study is hospital admission
Time frame: 30 days
Return of spontaneous circulation (ROSC)
Time frame: 30 days
24-hr survival
Time frame: 24 hours
Neurological and overall outcome at hospital discharge or at day 30, whichever came first
Time frame: 30 days
Symptomatic intracranial haemorrhage (ICH) up to hospital discharge or day 30, whichever came first
Time frame: 30 days
Major bleeds up to hospital discharge or day 30, whichever came first
Time frame: 30 days
The record gives a start of Jan 2004, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase